Jardy Met 12.5/1000 tablet is a combination medication that contains two active ingredients: Empagliflozin & Metformin. It is an oral antidiabetic drug used in the management of type 2 diabetes mellitus. Empagliflozin belongs to the class of SGLT2 inhibitors, which helps lower blood sugar levels by reducing glucose reabsorption in the kidneys. Metformin, on the other hand, is a biguanide that improves insulin sensitivity and reduces glucose production in the liver. The combination of these two drugs provides complementary effects in controlling blood sugar levels.
- Type 2 Diabetes Management: Jardy Met 12.5/1000 tablet is prescribed for the treatment of type 2 diabetes mellitus in adults. It is used to help lower blood sugar levels and improve glycemic control when lifestyle changes (diet and exercise) alone are not sufficient.
Like all medications, Jardy Met 12.5/1000 tablet may cause side effects in some individuals. Common side effects may include:
- Urinary Tract Infections: Empagliflozin may increase the risk of urinary tract infections in some patients.
- Genital Infections: Some individuals may experience genital yeast infections due to the effects of empagliflozin.
- Hypoglycemia: In rare cases, taking Jardy Met 12.5/1000 tablet may cause low blood sugar levels (hypoglycemia), especially if combined with other antidiabetic medications.
- Gastrointestinal Issues: Metformin can sometimes cause stomach upset, nausea, or diarrhea in certain individuals.
- Dehydration: Empagliflozin may lead to increased urination and potential dehydration, particularly in susceptible individuals.
- Lactic Acidosis: While rare, metformin use has been associated with a severe condition called lactic acidosis, especially in individuals with kidney or liver problems.
It is essential to promptly report any persistent or severe side effects to a healthcare professional.
When Not to Use:
Certain situations and conditions may contraindicate the use of Jardy Met 12.5/1000 tablet:
- Type 1 Diabetes: This medication is not intended for the treatment of type 1 diabetes, as it does not produce insulin.
- Diabetic Ketoacidosis: Jardy Met 12.5/1000 tablet should not be used in cases of diabetic ketoacidosis, a potentially life-threatening condition.
- Severe Kidney or Liver Dysfunction: It is not recommended for individuals with severe kidney or liver impairment, as both drugs can affect these organs.
- Allergic Reactions: Individuals with known allergies to Empagliflozin, Metformin, or any other ingredients in the tablet should avoid its use.
Important Note: Jardy Met 12.5/1000 tablet should be used under the guidance and prescription of a qualified healthcare professional. The dosage and treatment duration should be individualized based on the patient’s medical history, response to treatment, and blood sugar levels.
Regular monitoring of blood glucose levels and kidney function is essential during treatment. Do not alter the dosage or stop taking the medication without consulting a healthcare professional. If you are pregnant, breastfeeding, or planning to become pregnant, discuss with your doctor before using this medication.
Disclaimer: The information provided here is for general knowledge purposes only and should not be considered as medical advice. Always seek the guidance of a qualified healthcare professional for personalized recommendations and advice regarding your specific health condition and treatment options.